Infectious disease

Biomedical/pharma, Infectious disease, Personal/public health, Public health, Women’s health

While a vast majority of women experience vaginal yeast infections, research has fallen short in providing an effective treatment approach. However, hope has emerged recently with the development of new model systems that allow exploration of the complex vaginal environment. Organ-on-chip models enable researchers to examine the interactions between human cells and microbes in a more accurate manner, offering the potential for the development of new therapies.
Antibiotic resistance is a major concern for humans and animals. Increasing pressure to move away from antibiotics has created space for new solutions for disease management. Animab’s oral monoclonal antibody platform is a promising alternative, effectively guarding against infection during a vulnerable period in an animal’s development.
Obulytix, a spin-off based on research results from Ghent University and KU Leuven, has built a platform that creates new ways to tackle bacterial infections. The innovative, phage lysin-based platform – leveraging the power of artificial intelligence – attracted a significant four-million-euro investment from Boehringer Ingelheim Venture Fund, Qbic, and Gemma Frisius Fund.